Literature-reported optimized formulation B-2
Component: 113-AA-C8C14 | Molar ratio: 35 | Role: Ionizable lipid
sales@dcchemicals.com
113-AA-C8C14
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Literature-reported optimized formulation B-2
Component: DOPE | Molar ratio: 16 | Role: Helper phospholipid
Literature-reported optimized formulation B-2
Component: Cholesterol | Molar ratio: 46.5 | Role: Sterol lipid
Literature-reported optimized formulation B-2
Component: DMG-PEG2000 | Molar ratio: 0.5 | Role: PEG lipid
Reported observation
Fig. S14 Encapsulation efficiency 90.3 ± 3.0% RiboGreen assay
Reported observation
Fig. S14 Diameter 96.7 ± 1.0 nm DLS hydrodynamic size
Reported observation
Fig. S14 PDI 0.09 ± 0.05 DLS
Reported observation
Fig. S14 Zeta potential −16.7 ± 0.2 mV DLS
Reported observation
Fig. S14 Apparent pKa 6.66 LNP value · TNS assay
Reported observation
Fig. S13 Splenic expression 57-fold vs Dlin-MC3-DMA spleen SORT · luciferase mRNA
Reported observation
Fig. S13 Spleen/liver ratio 7-fold vs Dlin-MC3-DMA spleen SORT
Reported observation
Fig. 4 / S23 Tumor growth inhibition 2.3-fold improvement vs comparator LNP
Reported observation
Fig. 4H–I Tumor CAR+ T cells 2.7× / 3.5× CD8+ / CD4+ infiltration vs comparator
Reported observation
Fig. 4C Survival >50% at day 30 comparator median survival: 22 days